Colitis and Crohn's Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease

Ajit Sood; Vineet Ahuja; Vandana Midha; Saroj Kant Sinha; C. Ganesh Pai; Saurabh Kedia; Varun Mehta; Sawan Bopanna; Philip Abraham; Rupa Banerjee; Shobna Bhatia; Karmabir Chakravartty; Sunil Dadhich; Devendra Desai; Manisha Dwivedi; Bhabhadev Goswami; Kirandeep Kaur; Rajeev Khosla; Ajay Kumar; Ramit Mahajan; S. P. Misra; Kiran Peddi; Shivaram Prasad Singh; Arshdeep Singh

doi:10.5217/ir.2019.09176

Colitis and Crohn's Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease

Ajit Sood
, Vineet Ahuja
, Vandana Midha
, Saroj Kant Sinha
, C. Ganesh Pai
, Saurabh Kedia
, Varun Mehta
, Sawan Bopanna
, Philip Abraham
, Rupa Banerjee
, Shobna Bhatia
, Karmabir Chakravartty
, Sunil Dadhich
, Devendra Desai
, Manisha Dwivedi
, Bhabhadev Goswami
, Kirandeep Kaur
, Rajeev Khosla
, Ajay Kumar
, Ramit Mahajan

S. P. Misra, Kiran Peddi, Shivaram Prasad Singh, Arshdeep Singh

Department of Gastroenterology and Hepatology, Kasturba Medical College, Manipal

Research output: Contribution to journal › Article › peer-review

17 Citations (Scopus)

Abstract

Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations based on literature evidence (randomized trials, and observational studies), clinical practice, and expert opinion on use of 5-ASA in IBD by Indian gastroenterologists. The aim is to aid practitioners in selecting appropriate treatment strategies and facilitate optimal use of 5-ASA in patients with IBD. (Intest Res 2020;18:355-378)

Original language	English
Pages (from-to)	355-378
Number of pages	24
Journal	Intestinal Research
Volume	18
Issue number	4
DOIs	https://doi.org/10.5217/ir.2019.09176
Publication status	Published - 2020

All Science Journal Classification (ASJC) codes

Gastroenterology

Access to Document

10.5217/ir.2019.09176

Cite this

Sood, A., Ahuja, V., Midha, V., Sinha, S. K., Pai, C. G., Kedia, S., Mehta, V., Bopanna, S., Abraham, P., Banerjee, R., Bhatia, S., Chakravartty, K., Dadhich, S., Desai, D., Dwivedi, M., Goswami, B., Kaur, K., Khosla, R., Kumar, A., ... Singh, A. (2020). Colitis and Crohn's Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease. Intestinal Research, 18(4), 355-378. https://doi.org/10.5217/ir.2019.09176

@article{65930ec093c0404fa1ea4980a6982796,

title = "Colitis and Crohn's Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease",

abstract = "Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations based on literature evidence (randomized trials, and observational studies), clinical practice, and expert opinion on use of 5-ASA in IBD by Indian gastroenterologists. The aim is to aid practitioners in selecting appropriate treatment strategies and facilitate optimal use of 5-ASA in patients with IBD. (Intest Res 2020;18:355-378)",

author = "Ajit Sood and Vineet Ahuja and Vandana Midha and Sinha, \{Saroj Kant\} and Pai, \{C. Ganesh\} and Saurabh Kedia and Varun Mehta and Sawan Bopanna and Philip Abraham and Rupa Banerjee and Shobna Bhatia and Karmabir Chakravartty and Sunil Dadhich and Devendra Desai and Manisha Dwivedi and Bhabhadev Goswami and Kirandeep Kaur and Rajeev Khosla and Ajay Kumar and Ramit Mahajan and Misra, \{S. P.\} and Kiran Peddi and Singh, \{Shivaram Prasad\} and Arshdeep Singh",

note = "Publisher Copyright: {\textcopyright} 1988 {\textcopyright} 1988 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology.",

year = "2020",

doi = "10.5217/ir.2019.09176",

language = "English",

volume = "18",

pages = "355--378",

journal = "Intestinal Research",

issn = "1598-9100",

publisher = "Korean Association for the Study of Intestinal Diseases",

number = "4",

}

Sood, A, Ahuja, V, Midha, V, Sinha, SK, Pai, CG, Kedia, S, Mehta, V, Bopanna, S, Abraham, P, Banerjee, R, Bhatia, S, Chakravartty, K, Dadhich, S, Desai, D, Dwivedi, M, Goswami, B, Kaur, K, Khosla, R, Kumar, A, Mahajan, R, Misra, SP, Peddi, K, Singh, SP & Singh, A 2020, 'Colitis and Crohn's Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease', Intestinal Research, vol. 18, no. 4, pp. 355-378. https://doi.org/10.5217/ir.2019.09176

TY - JOUR

T1 - Colitis and Crohn's Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease

AU - Sood, Ajit

AU - Ahuja, Vineet

AU - Midha, Vandana

AU - Sinha, Saroj Kant

AU - Pai, C. Ganesh

AU - Kedia, Saurabh

AU - Mehta, Varun

AU - Bopanna, Sawan

AU - Abraham, Philip

AU - Banerjee, Rupa

AU - Bhatia, Shobna

AU - Chakravartty, Karmabir

AU - Dadhich, Sunil

AU - Desai, Devendra

AU - Dwivedi, Manisha

AU - Goswami, Bhabhadev

AU - Kaur, Kirandeep

AU - Khosla, Rajeev

AU - Kumar, Ajay

AU - Mahajan, Ramit

AU - Misra, S. P.

AU - Peddi, Kiran

AU - Singh, Shivaram Prasad

AU - Singh, Arshdeep

PY - 2020

Y1 - 2020

N2 - Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations based on literature evidence (randomized trials, and observational studies), clinical practice, and expert opinion on use of 5-ASA in IBD by Indian gastroenterologists. The aim is to aid practitioners in selecting appropriate treatment strategies and facilitate optimal use of 5-ASA in patients with IBD. (Intest Res 2020;18:355-378)

AB - Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations based on literature evidence (randomized trials, and observational studies), clinical practice, and expert opinion on use of 5-ASA in IBD by Indian gastroenterologists. The aim is to aid practitioners in selecting appropriate treatment strategies and facilitate optimal use of 5-ASA in patients with IBD. (Intest Res 2020;18:355-378)

UR - https://www.scopus.com/pages/publications/85113209949

UR - https://www.scopus.com/pages/publications/85113209949#tab=citedBy

U2 - 10.5217/ir.2019.09176

DO - 10.5217/ir.2019.09176

M3 - Article

AN - SCOPUS:85113209949

SN - 1598-9100

VL - 18

SP - 355

EP - 378

JO - Intestinal Research

JF - Intestinal Research

IS - 4

ER -

Colitis and Crohn's Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this